| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da9de6ace7a3d4ab7047f6611fade1cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24dfa599a776108f424b30ed919127a9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2002-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51cf5b1e63f0429057069618768fdf3e |
| publicationDate |
2003-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03041710-A1 |
| titleOfInvention |
Methods for preventing or treating disease mediateb by toxin-secreting bacteria |
| abstract |
Methods and pharmaceutical compositions for preventing and treating disease mediated by toxin-secreting bacteria. Inventive methods and compositions are suited to preventing or treating infections caused by bacterial toxins that enter host cells via receptor-mediated endocytosis (e.g., the anthrax and diphtheria toxins). Methods comprise a step of administering to an individual a pharmaceutical composition that includes an effective amount of an inhibitor of endosomal acidification. The inhibitor may be a primary amine, a carboxylic ionophore, or a selective inhibitor of the vacuolar proton pump (V-ATPase). The inhibitors of endosomal acidification may be employed in combination with other therapeutics such as antibiotics and antitoxins in order to prevent, treat or cure the disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016131962-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022174768-A1 |
| priorityDate |
2001-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |